Cargando…

The Organophosphate Paraoxon and Its Antidote Obidoxime Inhibit Thrombin Activity and Affect Coagulation In Vitro

Organophosphates (OPs) are potentially able to affect serine proteases by reacting with their active site. The potential effects of OPs on coagulation factors such as thrombin and on coagulation tests have been only partially characterized and potential interactions with OPs antidotes such as oximes...

Descripción completa

Detalles Bibliográficos
Autores principales: Golderman, Valery, Shavit-Stein, Efrat, Tamarin, Ilia, Rosman, Yossi, Shrot, Shai, Rosenberg, Nurit, Maggio, Nicola, Chapman, Joab, Eisenkraft, Arik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5045196/
https://www.ncbi.nlm.nih.gov/pubmed/27689805
http://dx.doi.org/10.1371/journal.pone.0163787
_version_ 1782457075626934272
author Golderman, Valery
Shavit-Stein, Efrat
Tamarin, Ilia
Rosman, Yossi
Shrot, Shai
Rosenberg, Nurit
Maggio, Nicola
Chapman, Joab
Eisenkraft, Arik
author_facet Golderman, Valery
Shavit-Stein, Efrat
Tamarin, Ilia
Rosman, Yossi
Shrot, Shai
Rosenberg, Nurit
Maggio, Nicola
Chapman, Joab
Eisenkraft, Arik
author_sort Golderman, Valery
collection PubMed
description Organophosphates (OPs) are potentially able to affect serine proteases by reacting with their active site. The potential effects of OPs on coagulation factors such as thrombin and on coagulation tests have been only partially characterized and potential interactions with OPs antidotes such as oximes and muscarinic blockers have not been addressed. In the current study, we investigated the in vitro interactions between coagulation, thrombin, the OP paraoxon, and its antidotes obidoxime and atropine. The effects of these substances on thrombin activity were measured in a fluorescent substrate and on coagulation by standard tests. Both paraoxon and obidoxime but not atropine significantly inhibited thrombin activity, and prolonged prothrombin time, thrombin time, and partial thromboplastin time. When paraoxon and obidoxime were combined, a significant synergistic effect was found on both thrombin activity and coagulation tests. In conclusion, paraoxon and obidoxime affect thrombin activity and consequently alter the function of the coagulation system. Similar interactions may be clinically relevant for coagulation pathways in the blood and possibly in the brain.
format Online
Article
Text
id pubmed-5045196
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-50451962016-10-27 The Organophosphate Paraoxon and Its Antidote Obidoxime Inhibit Thrombin Activity and Affect Coagulation In Vitro Golderman, Valery Shavit-Stein, Efrat Tamarin, Ilia Rosman, Yossi Shrot, Shai Rosenberg, Nurit Maggio, Nicola Chapman, Joab Eisenkraft, Arik PLoS One Research Article Organophosphates (OPs) are potentially able to affect serine proteases by reacting with their active site. The potential effects of OPs on coagulation factors such as thrombin and on coagulation tests have been only partially characterized and potential interactions with OPs antidotes such as oximes and muscarinic blockers have not been addressed. In the current study, we investigated the in vitro interactions between coagulation, thrombin, the OP paraoxon, and its antidotes obidoxime and atropine. The effects of these substances on thrombin activity were measured in a fluorescent substrate and on coagulation by standard tests. Both paraoxon and obidoxime but not atropine significantly inhibited thrombin activity, and prolonged prothrombin time, thrombin time, and partial thromboplastin time. When paraoxon and obidoxime were combined, a significant synergistic effect was found on both thrombin activity and coagulation tests. In conclusion, paraoxon and obidoxime affect thrombin activity and consequently alter the function of the coagulation system. Similar interactions may be clinically relevant for coagulation pathways in the blood and possibly in the brain. Public Library of Science 2016-09-30 /pmc/articles/PMC5045196/ /pubmed/27689805 http://dx.doi.org/10.1371/journal.pone.0163787 Text en © 2016 Golderman et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Golderman, Valery
Shavit-Stein, Efrat
Tamarin, Ilia
Rosman, Yossi
Shrot, Shai
Rosenberg, Nurit
Maggio, Nicola
Chapman, Joab
Eisenkraft, Arik
The Organophosphate Paraoxon and Its Antidote Obidoxime Inhibit Thrombin Activity and Affect Coagulation In Vitro
title The Organophosphate Paraoxon and Its Antidote Obidoxime Inhibit Thrombin Activity and Affect Coagulation In Vitro
title_full The Organophosphate Paraoxon and Its Antidote Obidoxime Inhibit Thrombin Activity and Affect Coagulation In Vitro
title_fullStr The Organophosphate Paraoxon and Its Antidote Obidoxime Inhibit Thrombin Activity and Affect Coagulation In Vitro
title_full_unstemmed The Organophosphate Paraoxon and Its Antidote Obidoxime Inhibit Thrombin Activity and Affect Coagulation In Vitro
title_short The Organophosphate Paraoxon and Its Antidote Obidoxime Inhibit Thrombin Activity and Affect Coagulation In Vitro
title_sort organophosphate paraoxon and its antidote obidoxime inhibit thrombin activity and affect coagulation in vitro
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5045196/
https://www.ncbi.nlm.nih.gov/pubmed/27689805
http://dx.doi.org/10.1371/journal.pone.0163787
work_keys_str_mv AT goldermanvalery theorganophosphateparaoxonanditsantidoteobidoximeinhibitthrombinactivityandaffectcoagulationinvitro
AT shavitsteinefrat theorganophosphateparaoxonanditsantidoteobidoximeinhibitthrombinactivityandaffectcoagulationinvitro
AT tamarinilia theorganophosphateparaoxonanditsantidoteobidoximeinhibitthrombinactivityandaffectcoagulationinvitro
AT rosmanyossi theorganophosphateparaoxonanditsantidoteobidoximeinhibitthrombinactivityandaffectcoagulationinvitro
AT shrotshai theorganophosphateparaoxonanditsantidoteobidoximeinhibitthrombinactivityandaffectcoagulationinvitro
AT rosenbergnurit theorganophosphateparaoxonanditsantidoteobidoximeinhibitthrombinactivityandaffectcoagulationinvitro
AT maggionicola theorganophosphateparaoxonanditsantidoteobidoximeinhibitthrombinactivityandaffectcoagulationinvitro
AT chapmanjoab theorganophosphateparaoxonanditsantidoteobidoximeinhibitthrombinactivityandaffectcoagulationinvitro
AT eisenkraftarik theorganophosphateparaoxonanditsantidoteobidoximeinhibitthrombinactivityandaffectcoagulationinvitro
AT goldermanvalery organophosphateparaoxonanditsantidoteobidoximeinhibitthrombinactivityandaffectcoagulationinvitro
AT shavitsteinefrat organophosphateparaoxonanditsantidoteobidoximeinhibitthrombinactivityandaffectcoagulationinvitro
AT tamarinilia organophosphateparaoxonanditsantidoteobidoximeinhibitthrombinactivityandaffectcoagulationinvitro
AT rosmanyossi organophosphateparaoxonanditsantidoteobidoximeinhibitthrombinactivityandaffectcoagulationinvitro
AT shrotshai organophosphateparaoxonanditsantidoteobidoximeinhibitthrombinactivityandaffectcoagulationinvitro
AT rosenbergnurit organophosphateparaoxonanditsantidoteobidoximeinhibitthrombinactivityandaffectcoagulationinvitro
AT maggionicola organophosphateparaoxonanditsantidoteobidoximeinhibitthrombinactivityandaffectcoagulationinvitro
AT chapmanjoab organophosphateparaoxonanditsantidoteobidoximeinhibitthrombinactivityandaffectcoagulationinvitro
AT eisenkraftarik organophosphateparaoxonanditsantidoteobidoximeinhibitthrombinactivityandaffectcoagulationinvitro